🔎 Trials Near Me

Utama › Melanoma › Virginia › Arlington

Kajian klinikal Melanoma di Arlington, VA

20 kajian untuk Melanoma sedang mencari peserta di lokasi dalam dan sekitar Arlington (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Mengambil pesertaFasa 1
  • Inova Schar Cancer Institute, Fairfax · 11 mi jauh
  • NEXT Virginia, Fairfax · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06270706

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

Mengambil pesertaFasa 1
  • Inova Schar Cancer Infusion Pharmacy, Fairfax · 11 mi jauh
  • Inova Schar Cancer, Fairfax · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07519655

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

Mengambil pesertaFasa 2
  • Inova Schar Cancer Institute ( Site 4046), Fairfax · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06961006

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Mengambil pesertaFasa 2
  • Inova Fairfax Hospital, Falls Church · 4 mi jauh
  • Inova Schar Cancer Institute, Fairfax · 11 mi jauh
  • Inova Fair Oaks Hospital, Fairfax · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05136196

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Mengambil pesertaFasa 3
  • Inova Schar Cancer Institute, Fairfax · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06246916

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Mengambil pesertaFasa 1/2
  • Virginia Cancer Specialists-Fairfax, Fairfax · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07287917

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Mengambil pesertaFasa 1
  • Virginia Cancer Specialists, Fairfax · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT04913285

Project: Every Child for Younger Patients With Cancer

Mengambil pesertaKajian pemerhatian
  • Inova Fairfax Hospital, Falls Church · 4 mi jauh
Sehingga umur 25 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT02402244

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Mengambil pesertaFasa 1/2
  • Research Site, Fairfax · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT07115043

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

Mengambil pesertaFasa 1/2
  • Clinical Trial Site, Fairfax · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT07749586

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

Mengambil pesertaFasa 1/2
  • Virginia Cancer Specialists, Fairfax · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT06330064

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Mengambil pesertaFasa 1/2
  • Next Oncology Virginia, Fairfax · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Mei 2026 · NCT05379985

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

Mengambil pesertaFasa 1
  • NEXT Oncology - Virginia, Fairfax · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Apr 2026 · NCT06326411

A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors

Mengambil pesertaFasa 1
  • NEXT Virginia, Fairfax · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Jan 2026 · NCT07317505

Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

Mengambil pesertaFasa 1
  • NEXT Oncology, Fairfax · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Nov 2025 · NCT06332755

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Mengambil pesertaFasa 1/2
  • Research Site 102, Fairfax · 11 mi jauh
  • Research Site 112, Fairfax · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Nov 2025 · NCT05914116

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Mengambil pesertaFasa 1/2
  • Virginia Cancer Specialists, Fairfax · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Okt 2025 · NCT04370587

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Mengambil pesertaFasa 1/2
  • Virginia Cancer Specialists, Fairfax · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Feb 2025 · NCT05669430

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Mengambil pesertaFasa 1/2
  • NEXT Virginia, Fairfax · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Jan 2025 · NCT06090266

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

Mengambil pesertaFasa 1
  • Next Oncology, Virginia Cancer Specialists, Fairfax · 11 mi jauh
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Jan 2024 · NCT05746897

Kajian Melanoma di bandar lain

Kajian lain di Arlington

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.